Insider
AtriCure, Inc.ATRC

AtriCure introduces new EnCompass clamp and publishes hybrid AF therapy guide

AtriCure announced the first worldwide use of the Isolator® Synergy™ EnCompass® clamp in Montreal hospitals and unveiled a Hybrid Best Practices Guide developed by 25 authors from 10 countries

Verified against 4 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
white and red exit sign
Photo by Cory Mogk on Unsplash
25 authors
Guide authors
10 countries
Participating countries

Key points

  • The company said surgeons at Hôpital du Sacré‑Coeur‑de‑Montréal and Fondation de l'Hôpital du Sacré‑Coeur‑de‑Montréal completed the first case with the Isolator® Synergy™ EnCompass® clamp on Oct.
  • The guide targets patients with long‑standing persistent atrial fibrillation (LSPAF) for whom hybrid therapy is considered a durable treatment
  • The clamp delivers adaptive RF energy in real time, which the company says reduces guesswork when creating lesions, and the two sizes increase procedural flexibility

What happened

The company said surgeons at Hôpital du Sacré‑Coeur‑de‑Montréal and Fondation de l'Hôpital du Sacré‑Coeur‑de‑Montréal completed the first case with the Isolator® Synergy™ EnCompass® clamp on Oct. 14

The clamp provides real‑time, patient‑specific adaptive radiofrequency (RF) energy, ensuring consistent lesion quality in every case

It is offered in two versions – standard and long – enabling sizing to match patient anatomy

At the same time, AtriCure released a Hybrid Best Practices Guide with contributions from 25 authors in 10 countries to standardize combined epicardial‑endocardial hybrid AF therapy

Who it matters to

The guide targets patients with long‑standing persistent atrial fibrillation (LSPAF) for whom hybrid therapy is considered a durable treatment

Proof of efficacy

The clamp delivers adaptive RF energy in real time, which the company says reduces guesswork when creating lesions, and the two sizes increase procedural flexibility

The guide consolidates international experience to unify approaches, potentially improving treatment consistency

Next step

Further use of the clamp at other centers and adoption of the guide’s recommendations will determine its impact on AF therapy; the company has not announced additional regulatory filings

Original sources

  1. LinkedIn-USA,ASIA,CANADA-urn:li:ugcPost:7515788900230037504October 13, 2026SHA-256 of our archived copy a4d9fc7fc085…
  2. Twitter-2110385657583403327October 14, 2026SHA-256 of our archived copy 0040a068a069…
  3. LinkedIn-USA,ASIA,CANADA-urn:li:share:7516151118033338369October 14, 2026SHA-256 of our archived copy 70a8b218dd48…
  4. Twitter-2110464430970388765October 14, 2026SHA-256 of our archived copy 3e0f555da72e…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards